<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02275611</url>
  </required_header>
  <id_info>
    <org_study_id>12-1862a</org_study_id>
    <nct_id>NCT02275611</nct_id>
  </id_info>
  <brief_title>Oxytocin Treatment of Alcohol Dependence</brief_title>
  <acronym>OT-ETOH2</acronym>
  <official_title>Oxytocin Treatment of Alcohol Dependence: A Randomized, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test in individuals who have alcohol dependence (alcohol addiction) the&#xD;
      hypotheses 1) that intranasal oxytocin treatment will decrease withdrawal symptoms during&#xD;
      medical detoxification and 2) that intranasal oxytocin treatment for 12 weeks in the&#xD;
      outpatient setting will decrease drinking.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design This is a randomized, double blind, placebo-controlled early phase II clinical&#xD;
      trial.&#xD;
&#xD;
      Recruitment: The study has 2 phases. The first is testing intranasal treatments (oxytocin&#xD;
      [OT], placebo) on alcohol withdrawal (the inpatient phase) and the second is testing&#xD;
      intranasal treatments on alcohol drinking, craving and anxiety over 12 weeks in the&#xD;
      outpatient setting (the outpatient phase). Subjects for the inpatient phase will only be&#xD;
      recruited from patients admitted to Freedom House (FRH, mental health center in Chapel Hill,&#xD;
      NC) for medical detoxification from alcohol within the last 36 hours. Subjects for the&#xD;
      outpatient phase of the study will be inpatients at FRH or the University of North Carolina&#xD;
      (UNC) Hospitals who are near the end of their inpatient stay (medical detoxification has been&#xD;
      or is nearly completed). Subjects in the inpatient phase of the study at FRH may continue&#xD;
      into the outpatient phase after discharge. Subjects for the outpatient phase will also be&#xD;
      heavy drinkers from the community who are screened during an initial outpatient clinic visit.&#xD;
&#xD;
      Patients newly admitted to FRH to treat alcohol withdrawal will undergo a brief screening&#xD;
      that includes: 1) a recent and past alcohol use interview (Time Line Follow Back, TLFB) and&#xD;
      history of alcohol withdrawal interview; 2) a brief psychiatric interview; 3 ) a score on the&#xD;
      10-item CIWA scale of alcohol withdrawal symptoms; 4) a review of potential medical exclusion&#xD;
      criteria including a history of seizures or delirium tremens; 5) a spot urine pregnancy test&#xD;
      on all prospective female subjects.&#xD;
&#xD;
      Recruitment into the outpatient phase (treatment of outpatient drinking): Patients who&#xD;
      undergo medical detoxification from alcohol will be recruited from FRH or from UNC Hospitals&#xD;
      toward the end of their admission for participation in a trial to test the efficacy of&#xD;
      intranasal OT vs. placebo treatment on alcohol drinking, alcohol craving and anxiety during a&#xD;
      12-week outpatient treatment period. They will be screened to see if they meet study&#xD;
      criteria. These individuals will read and sign the Breath Alcohol Policy that states that if&#xD;
      their Breathalyzer reading at the beginning of an outpatient clinic visit is &gt;.08 they will&#xD;
      not be assessed at that visit and will not drive themselves home but rather will accept a&#xD;
      ride from a family member, friend or a cab driver.&#xD;
&#xD;
      Other individuals will be recruited from the community for participation in the outpatient&#xD;
      phase of the study who have responded to a radio ad, a UNC listserve ad, a flyer, have been&#xD;
      referred by local clinicians or have otherwise become aware of the study. These prospective&#xD;
      subjects will undergo a telephone screening interview. If they appear to meet criteria over&#xD;
      the phone, they will be further screened during an outpatient clinic visit. They must sign&#xD;
      the Breath Alcohol Policy.&#xD;
&#xD;
      Inpatient Treatment of Withdrawal Protocol and Measures: Subjects who enroll in the study&#xD;
      shortly after being admitted to FRH will immediately complete the State portion of the&#xD;
      Spielberger State-Trait Anxiety Inventory (SSTAI) and the Penn Alcohol Craving Scale (PACS).&#xD;
      This will be followed by self-administration of their first intranasal test dose under&#xD;
      supervision of research personnel. These subjects will self-administer additional intranasal&#xD;
      test doses at 1 and 3 h after the initial dose and then on the evening of that first day of&#xD;
      admission. On subsequent admission days at FRH, subjects will self-administer intranasal test&#xD;
      doses 3 times per day. After the first intranasal test dose, blood (15 ml) and urine samples&#xD;
      will be obtained from subjects at FRH by research personnel for complete blood count (CBC),&#xD;
      electrolytes, blood urea nitrogen (BUN), creatinine, glucose, albumin, liver function tests,&#xD;
      urinalysis and urine toxicology which will be transported to and run at the UNC Hospital&#xD;
      laboratory.&#xD;
&#xD;
      Between the 1st and 3rd initial intranasal test doses, research personnel will complete a&#xD;
      more detailed psychiatric interview. Subjects will also complete the University of Rhode&#xD;
      Island Change Assessment Scale to assess their stage of motivation to stop or cut back on&#xD;
      their drinking, the Drinker's Inventory of Consequences to assess the spectrum of&#xD;
      consequences related to drinking, the Family History of Alcoholism Module to assess family&#xD;
      history of alcohol problems, the Patient Health Questionnaire (PHQ) to assess symptoms of&#xD;
      depression and a Demographic Questionnaire. During the first 2 inpatient days, vital signs&#xD;
      and CIWA scores will be obtained (by FRH personnel) every 4 hours or whenever subjects report&#xD;
      or nurses observe the onset of withdrawal symptoms. On the 3rd inpatient day, these measures&#xD;
      will be obtained 3 times. And on subsequent inpatient days, these measures will be obtained&#xD;
      once each day and whenever withdrawal symptoms increase. Subjects will complete the PACS and&#xD;
      the SSTAI prior to administration of the 2nd test dose on each inpatient day starting the day&#xD;
      after they enter the study. Blood will be drawn early on inpatient day 3 for electrolyte&#xD;
      measurements.&#xD;
&#xD;
      In all subjects participating in the inpatient phase of the study, lorazepam (2 mg), a&#xD;
      standard medication to decrease withdrawal symptoms, will be administered by mouth (PO)&#xD;
      whenever CIWA scores are ≥ 7. CIWA scores will be repeated 1 h after each lorazepam dose and&#xD;
      another dose given if the CIWA score remains ≥ 7. Also, lorazepam (2 mg) will be administered&#xD;
      if subjects are found to have any of the following elevated vital signs (even if CIWA scores&#xD;
      remain low): pulse &gt; 110; diastolic blood pressure &gt; 100; systolic blood pressure &gt; 160.&#xD;
      Vital signs (as well as CIWA) will be repeated 1 h after each lorazepam dose and another dose&#xD;
      will be given if any of the elevated measures persist. If a subject's CIWA score remains ≥ 7,&#xD;
      pulse remains &gt; 110 or diastolic blood pressure remains &gt; 100 after 8 consecutive lorazepam&#xD;
      doses, systolic blood pressure remains &gt; 160 after 3 lorazepam doses, or CIWA scores steadily&#xD;
      increase despite receiving 3 consecutive lorazepam doses or dangerous symptoms develop (e.g.,&#xD;
      the onset of hallucinations), a more aggressive detoxification regimen will be initiated and&#xD;
      the subject will be dropped from the study. All patients admitted to FRH for alcohol&#xD;
      detoxification receive thiamine, folate and multivitamins supplementation.&#xD;
&#xD;
      Initiating Outpatient Test Treatment: Subjects recruited into the outpatient phase of the&#xD;
      study at the end of an inpatient admission for medical detoxification from alcohol will be&#xD;
      randomized to a treatment group and begin intranasal test treatment during their first&#xD;
      outpatient clinic visit after discharge from FRH or UNC Hospitals. Subjects recruited from&#xD;
      the community will be randomized and begin intranasal test treatments at a outpatient clinic&#xD;
      visit scheduled shortly after their screening clinic visit if assessments at the latter visit&#xD;
      indicate they meet inclusion criteria and not exclusion criteria. Several measures will be&#xD;
      obtained at the beginning of the clinic visit when subjects begin self-administration of test&#xD;
      treatments: Breathalyzer reading, CIWA rating, TLFB interview assessment of recent alcohol&#xD;
      consumption, self-ratings on the SSTAI and PACS. Research personnel will then instruct&#xD;
      subjects in intranasal self-administration technique and then observe subjects take their&#xD;
      first intranasal test dose. Subjects will be given written instructions on intranasal&#xD;
      self-administration technique, cleaning the spray bottle nozzle after each dose, storing&#xD;
      spray bottles between doses and contacting study personnel if they have question, difficulty&#xD;
      with the self-administration procedure or may be experiencing side effects. At the end of the&#xD;
      clinic visit, subjects will take home a 60 ml spray bottle (that ejects 0.1 ml metered dose&#xD;
      per insufflation) containing 25 ml of test solution which they will use to self-administer&#xD;
      test treatment doses twice daily (6 insufflations/dose).&#xD;
&#xD;
      Outpatient clinic visits during the treatment period: Subjects will have follow-up outpatient&#xD;
      clinic visits at weeks 1, 2, 3, 4, 6, 8, 10 and 12 after starting intranasal test treatments.&#xD;
      Outpatient visits will take place in the Psychiatry Clinics in the UNC Neurosciences Hospital&#xD;
      or the Alcohol and Substance Abuse Program (ASAP) clinic which is located off of the UNC&#xD;
      campus on a bus line making it more convenient for participants to commute and park thereby&#xD;
      facilitating their compliance with the outpatient portion of the study. To enhance&#xD;
      continuity, the first visit will be 2-3 days after the clinic visit during which intranasal&#xD;
      test treatments are started. At each clinic visit, a Breathalyzer reading, a CIWA score and&#xD;
      vital signs will be obtained, a TLFB interview administered to quantify daily alcohol intake&#xD;
      since the last clinic visit, and the SSTAI, PACS and PHQ questionnaires will be completed.&#xD;
      Subjects will be given a fresh 60 ml intranasal spray bottle containing 25 ml of test&#xD;
      substance at clinic visits every 2 weeks. At each clinic visit, subjects' spray bottles will&#xD;
      be weighed to monitor compliance. Their intranasal self-administration technique will be&#xD;
      reviewed and, if necessary, subjects will be reinstructed in proper technique. At 4, 8 and 12&#xD;
      weeks, blood will be drawn for CBC, liver functions, electrolytes, BUN, creatinine, and a&#xD;
      urine sample will be obtained for drug screening and pregnancy tests on all female subjects.&#xD;
&#xD;
      During each clinic visit, 15 minutes of substance use counseling (Medical Management) will be&#xD;
      provided.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Clinical Institute Withdrawal Assessment for Alcohol (CIWA) Score</measure>
    <time_frame>Change in scores from before initiation of intranasal test treatment and the first 48 hours after initiation of intranasal test treatments</time_frame>
    <description>The Clinical Institute Withdrawal Assessment for Alcohol (CIWA) measure is a ten item measure of alcohol withdrawal symptoms. The CIWA total score is the summation of 10 questions, with a range from 0 (little to no withdrawal) to 67 (worse alcohol withdrawal).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total mg of Lorazepam for Detoxification</measure>
    <time_frame>48 hours after initiation of intranasal test doses</time_frame>
    <description>Cumulative lorazepam received (2 mg doses)&#xD;
After initiation of test treatments, CIWA scores and vital signs were obtained every 4 hours or whenever subjects or staff reported/observed significant increases in symptoms. Lorazepam (2 mg dose) was given if CIWA scores were &gt;7, diastolic blood pressure rose to &gt;120, or heart rate rose to &gt;110. An additional 2 mg was given 1 hour after each lorazepam dose if CIWA scores and/or vital signs remained elevated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage Heavy Drinking Days</measure>
    <time_frame>90 days prior to admission and 4 weeks in the outpatient setting</time_frame>
    <description>A heavy drinking day is defined by consumption of 5 or more standard drinks for men, 4 or more standard drinks for women. The outcome measure is the change in percentage of heavy drinking days as determine by the Timeline Followback interview between the baseline 90 day period and the first 4 weeks of intranasal test treatment in the outpatient setting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Alcohol Withdrawal</condition>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Intranasal oxytocin spray (Syntocinon Spray)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TID inpatient; BID outpatient for 12 wks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal Placebo Spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TID inpatient; BID outpatient for 12 wks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intranasal oxytocin spray</intervention_name>
    <description>Administration of oxytocin in a nasal spray</description>
    <arm_group_label>Intranasal Placebo Spray</arm_group_label>
    <arm_group_label>Intranasal oxytocin spray (Syntocinon Spray)</arm_group_label>
    <other_name>Syntocinon Spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Placebo Spray</intervention_name>
    <description>Intranasal Placebo Spray</description>
    <arm_group_label>Intranasal Placebo Spray</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion Criteria for the inpatient phase (alcohol withdrawal treatment) of the study&#xD;
&#xD;
             1. Meeting criteria for DSM-IV (Diagnostic and Statistical Manual-IV-TR) alcohol&#xD;
             dependence.&#xD;
&#xD;
             *2. At least one prior episode of DSM-IV alcohol withdrawal as assessed by SCID&#xD;
             Alcohol Dependence Module or scoring &gt; 6 on the CIWA scale since admission to the&#xD;
             inpatient unit, or having any of the following elevated vital signs since admission:&#xD;
             pulse &gt; 110; diastolic blood pressure &gt; 100; systolic blood pressure &gt; 160.&#xD;
&#xD;
             3. At least 12 heavy drinking days in the 28 days prior to enrollment in the study. A&#xD;
             heavy drinking day is defined as &gt;5 standard drinks for men or &gt;4 standard drinks for&#xD;
             women.&#xD;
&#xD;
             4. Women who are able to conceive children must be on an effective form of birth&#xD;
             control such as oral contraceptives, intrauterine devices or the use of condoms with&#xD;
             spermicide.&#xD;
&#xD;
             5. Competency to give valid informed consent as indicated by a) a breathalyzer reading&#xD;
             at the time the consent form is signed showing an estimated blood alcohol level (BAL)&#xD;
             &lt;.08 gm/dL (the consent process is repeated when the BAL level has dropped to 0.00&#xD;
             gm/dL) and b) ability to understand the written informed consent form demonstrated by&#xD;
             correctly answering questions about the contents of the form after reading the consent&#xD;
             form without help (this will also determine whether prospective subjects can read and&#xD;
             understand the study questionnaires).&#xD;
&#xD;
             6. Ability to get to appointments either through personal or public transportation.&#xD;
&#xD;
          -  Inclusion Criteria for the outpatient phase of the study (treatment of heavy drinking)&#xD;
             for prospective subjects screened toward the end of their FRH or UNC inpatient stay&#xD;
             The same criteria as those listed above for the inpatient phase of the study apply&#xD;
             except for the criteria marked with an asterisk.&#xD;
&#xD;
          -  Inclusion Criteria for the outpatient phase of the study for prospective subjects&#xD;
             recruited from the community and screened during an initial outpatient clinic visit&#xD;
             The same criteria as those listed above for the inpatient alcohol withdrawal treatment&#xD;
             phase of the study apply except for having a previous history of alcohol withdrawal&#xD;
             (inclusion criterion #2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion Criteria for the inpatient alcohol withdrawal treatment phase of the study&#xD;
&#xD;
               -  1. History of alcohol withdrawal-related seizures, delirium tremens or&#xD;
                  hallucinations.&#xD;
&#xD;
                  2. Clinically significant medical disease that might interfere with the&#xD;
                  evaluation of the study medication or present a safety concern (e.g., renal&#xD;
                  insufficiency, cirrhosis, unstable hypertension, unstable diabetes mellitus,&#xD;
                  seizure disorder). Clinically significant psychiatric illnesses including any&#xD;
                  psychotic disorder, bipolar disorder, eating disorder, severe depression, or&#xD;
                  suicidal ideation.&#xD;
&#xD;
                  3. Other substance dependence disorder with the exceptions of nicotine or&#xD;
                  caffeine. Substance abuse disorders are not exclusionary.&#xD;
&#xD;
               -  4. Chronic or subchronic ( &gt;3 days in the week prior to admission or outpatient&#xD;
                  enrollment) treatment with/consumption of benzodiazepines, barbiturates,&#xD;
                  anticonvulsants or stimulants.&#xD;
&#xD;
               -  5. Receipt of &gt;6 mg of lorazepam or any dose of a long half-life benzodiazepine&#xD;
                  between admission for medical detoxification and beginning participation in the&#xD;
                  study (i.e., receiving the first intranasal dose of test treatment).&#xD;
&#xD;
                  6. AST or ALT (liver function tests) &gt; 5 times ULN (upper level of normal),&#xD;
                  bilirubin (liver function test) &gt; 1.5 X ULN, sodium &lt; 132 or &gt; 150 mMol/L,&#xD;
                  potassium &lt; 3.2 or &gt; 5.3 mMol/L.&#xD;
&#xD;
                  7. Women who are pregnant or breastfeeding. 8. Intent to participate in an&#xD;
                  additional alcohol treatment program other than Alcoholics Anonymous 9.&#xD;
                  Court-mandated participation in alcohol treatment or pending incarceration.&#xD;
&#xD;
          -  Exclusion Criteria for the outpatient phase of the study (treatment of heavy drinking)&#xD;
             for prospective subjects screened toward the end of their FRH or UNC inpatient stay&#xD;
             The same criteria as those listed above for the inpatient phase of the study apply&#xD;
             except for the criteria marked with an asterisk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cort A Pedersem, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>February 8, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2014</study_first_posted>
  <results_first_submitted>January 15, 2015</results_first_submitted>
  <results_first_submitted_qc>March 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2017</results_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Cort Pedersen, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>oxytocin</keyword>
  <keyword>alcohol withdrawal</keyword>
  <keyword>alcohol dependence</keyword>
  <keyword>alcoholism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The numbers of subjects recruited into the withdrawal study alone, outpatient study alone, or both = 13. Some people dropped out of the inpatient withdrawal phase after they completed that phase. Additional participants were added for the second, outpatient phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Comparator:Intranasal Oxytocin Spray (Syntocinon Spray)</title>
          <description>Syntocinon Spray 3-4 doses daily inpatient; 2 daily doses outpatient for 12 weeks.&#xD;
Inpatient Withdrawal</description>
        </group>
        <group group_id="P2">
          <title>Placebo Comparator: Intranasal Placebo Spray</title>
          <description>Placebo spray 3-4 doses daily inpatient; 2 daily doses outpatient for 12 weeks Inpatient Withdrawal</description>
        </group>
        <group group_id="P3">
          <title>Outpatient Treatment Intranasal Oxytocin Spray (Syntocinon)</title>
          <description>2 daily doses intranasal oxytocin spray for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>Outpatient Treatment Placebo Spray</title>
          <description>2 daily doses intranasal placebo spray for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Inpatient Withdrawal</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Outpatient Drinking</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intranasal Oxytocin Spray (Syntocinon)</title>
          <description>Syntocinon Spray 3-4 doses daily inpatient; 2 daily doses outpatient for 12 weeks intranasal oxytocin spray. Inpatient Withdrawal</description>
        </group>
        <group group_id="B2">
          <title>Intranasal Placebo Spray</title>
          <description>Placebo spray 3-4 doses daily inpatient; 2 daily doses outpatient for 12 weeks intranasal placebo spray. Inpatient Withdrawal</description>
        </group>
        <group group_id="B3">
          <title>Outpatient Treatment Intranasal Oxytocin Spray (Syntocinon)</title>
          <description>2 daily doses intranasal oxytocin spray for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Outpatient Treatment Placebo Spray</title>
          <description>2 daily doses intranasal placebo spray for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="8"/>
                    <count group_id="B4" value="5"/>
                    <count group_id="B5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Institute Withdrawal Assessment for Alcohol (CIWA)</title>
          <description>The Clinical Institute Withdrawal Assessment for Alcohol (CIWA) measure is a ten item measure of alcohol withdrawal symptoms. The CIWA total score is the summation of 10 questions, with a range from 0 (little to no withdrawal) to 67 (worse alcohol withdrawal).</description>
          <population>Only 4 oxytocin recipients and 4 placebo recipients were involved in the study of intranasal treatments on alcohol withdrawal as determined by CIWA scores</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.41" spread="1.45"/>
                    <measurement group_id="B2" value="5.57" spread="1.85"/>
                    <measurement group_id="B5" value="5.99" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Clinical Institute Withdrawal Assessment for Alcohol (CIWA) Score</title>
        <description>The Clinical Institute Withdrawal Assessment for Alcohol (CIWA) measure is a ten item measure of alcohol withdrawal symptoms. The CIWA total score is the summation of 10 questions, with a range from 0 (little to no withdrawal) to 67 (worse alcohol withdrawal).</description>
        <time_frame>Change in scores from before initiation of intranasal test treatment and the first 48 hours after initiation of intranasal test treatments</time_frame>
        <population>This assessment was done only in the inpatient withdrawal phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Oxytocin Spray (Syntocinon Spray)</title>
            <description>Syntocinon Spray 3-4 doses daily inpatient&#xD;
intranasal oxytocin spray: Administration of oxytocin in a nasal spray</description>
          </group>
          <group group_id="O2">
            <title>Intranasal Placebo Spray</title>
            <description>Placebo spray 3-4 doses daily inpatient&#xD;
intranasal oxytocin spray: Administration of oxytocin in a nasal spray&#xD;
Intranasal Placebo Spray: Intranasal Placebo Spray</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Institute Withdrawal Assessment for Alcohol (CIWA) Score</title>
          <description>The Clinical Institute Withdrawal Assessment for Alcohol (CIWA) measure is a ten item measure of alcohol withdrawal symptoms. The CIWA total score is the summation of 10 questions, with a range from 0 (little to no withdrawal) to 67 (worse alcohol withdrawal).</description>
          <population>This assessment was done only in the inpatient withdrawal phase.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.76" spread="1.95"/>
                    <measurement group_id="O2" value="1.01" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total mg of Lorazepam for Detoxification</title>
        <description>Cumulative lorazepam received (2 mg doses)&#xD;
After initiation of test treatments, CIWA scores and vital signs were obtained every 4 hours or whenever subjects or staff reported/observed significant increases in symptoms. Lorazepam (2 mg dose) was given if CIWA scores were &gt;7, diastolic blood pressure rose to &gt;120, or heart rate rose to &gt;110. An additional 2 mg was given 1 hour after each lorazepam dose if CIWA scores and/or vital signs remained elevated.</description>
        <time_frame>48 hours after initiation of intranasal test doses</time_frame>
        <population>This assessment was done only in the inpatient withdrawal phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Oxytocin Spray (Syntocinon Spray)</title>
            <description>Syntocinon Spray 3-4 doses daily inpatient</description>
          </group>
          <group group_id="O2">
            <title>Intranasal Placebo Spray</title>
            <description>Placebo spray 3-4 doses daily inpatient</description>
          </group>
        </group_list>
        <measure>
          <title>Total mg of Lorazepam for Detoxification</title>
          <description>Cumulative lorazepam received (2 mg doses)&#xD;
After initiation of test treatments, CIWA scores and vital signs were obtained every 4 hours or whenever subjects or staff reported/observed significant increases in symptoms. Lorazepam (2 mg dose) was given if CIWA scores were &gt;7, diastolic blood pressure rose to &gt;120, or heart rate rose to &gt;110. An additional 2 mg was given 1 hour after each lorazepam dose if CIWA scores and/or vital signs remained elevated.</description>
          <population>This assessment was done only in the inpatient withdrawal phase.</population>
          <units>cumulative lorazepam doses (mg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" spread="1.26"/>
                    <measurement group_id="O2" value="5.25" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage Heavy Drinking Days</title>
        <description>A heavy drinking day is defined by consumption of 5 or more standard drinks for men, 4 or more standard drinks for women. The outcome measure is the change in percentage of heavy drinking days as determine by the Timeline Followback interview between the baseline 90 day period and the first 4 weeks of intranasal test treatment in the outpatient setting.</description>
        <time_frame>90 days prior to admission and 4 weeks in the outpatient setting</time_frame>
        <population>This assessment was done only in the outpatient phase.</population>
        <group_list>
          <group group_id="O1">
            <title>Outpatient Treatment Intranasal Oxytocin Spray (Syntocinon)</title>
            <description>2 daily doses intranasal oxytocin spray for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Outpatient Treatment Placebo Spray</title>
            <description>2 daily doses intranasal placebo spray for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage Heavy Drinking Days</title>
          <description>A heavy drinking day is defined by consumption of 5 or more standard drinks for men, 4 or more standard drinks for women. The outcome measure is the change in percentage of heavy drinking days as determine by the Timeline Followback interview between the baseline 90 day period and the first 4 weeks of intranasal test treatment in the outpatient setting.</description>
          <population>This assessment was done only in the outpatient phase.</population>
          <units>percentage of heavy drinking days change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.377" spread="0.28"/>
                    <measurement group_id="O2" value="-0.972" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intranasal Oxytocin Spray (Syntocinon Spray)</title>
          <description>Syntocinon Spray 3-4 doses daily inpatient; 2 daily doses outpatient for 12 weeks&#xD;
intranasal oxytocin spray: Administration of oxytocin in a nasal spray</description>
        </group>
        <group group_id="E2">
          <title>Intranasal Placebo Spray</title>
          <description>Placebo spray 3-4 doses daily inpatient; 2 daily doses outpatient for 12 weeks&#xD;
intranasal oxytocin spray: Administration of oxytocin in a nasal spray&#xD;
Intranasal Placebo Spray: Intranasal Placebo Spray</description>
        </group>
        <group group_id="E3">
          <title>Outpatient Treatment Intranasal Oxytocin Spray (Syntocinon)</title>
          <description>2 daily doses intranasal oxytocin spray for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>Outpatient Treatment Placebo Spray</title>
          <description>2 daily doses intranasal placebo spray for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Cort A. Pedersen</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>(919) 966-4447</phone>
      <email>Cort_Pedersen@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

